NCT05726929 (ALGOS) is a NA clinical trial of Osteopathic treatment in Breast Cancer, sponsored by Institut Toulousain d'Ostéopathie.

Who is sponsoring NCT05726929?

NCT05726929 is sponsored by Institut Toulousain d'Ostéopathie.

What drugs are being tested in NCT05726929?

Interventions in NCT05726929: Osteopathic treatment, Capsaicin QUTENZA Patch (TAU).

What condition does NCT05726929 study?

NCT05726929 studies Breast Cancer, Neuropathic Pain.

Is NCT05726929 still recruiting?

NCT05726929 is currently completed. Last updated 18 February 2025.

Last reviewed 2025-02-18 · How we verify

NCT05726929: ALGOS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Algology in Oncology Osteopathic Support (ALGOS)

Completed NA Last updated 18 February 2025

What this trial tests

NA trial testing Osteopathic treatment in Breast Cancer in 12 participants. Completed in 8 December 2024.

Timeline

11 January 2023

Primary endpoint
8 December 2024

8 December 2024

Quick facts

Lead sponsor	Institut Toulousain d'Ostéopathie
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	12
Start date	11 January 2023
Primary completion	8 December 2024
Estimated completion	8 December 2024
Sites	1 location across France

Drugs / interventions tested

Osteopathic treatment
Capsaicin QUTENZA Patch (TAU)

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Neuropathic Pain — all drugs for Neuropathic Pain →

Sponsor

Institut Toulousain d'Ostéopathie

Who can join

Adults 18 to 80, any sex, with Breast Cancer or Neuropathic Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to evaluate the Impact of add-on osteopathic treatment in the algological course of patients treated for breast cancer : Randomized Controlled Trial.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Changes in biochemical markers following a spinal manipulation - a systematic review update.
Kovanur Sampath K, Treffel L, P Thomson O, Rodi JD, et al · · 2024 · cited 11× · PMID 37671460 · DOI 10.1080/10669817.2023.2252187
Emerging advances in drug delivery systems (DDSs) for optimizing cancer complications.
Li K, Guo B, Gu J, Ta N, et al · · 2025 · cited 8× · PMID 39759851 · DOI 10.1016/j.mtbio.2024.101375

Verify or expand the search:

Other trials of Osteopathic treatment

Trials testing the same drug.

NCT06822348 — Short-term Effects of Osteopathic Manipulations on Heart Rate Variability in Lung Cancer Patients - A Randomized Pilot S · NA · not yet recruiting
NCT07260422 — EVALUATION OF THE EFFECT OF OSTEOPATHIC TREATMENT ON CHRONIC NONSPECIFIC NECK PAIN · NA · completed
NCT04666415 — Impact of the Addition of a Specific and Personalized Body Approach by Osteopathic Treatment in the Care of Adolescents · NA · unknown
NCT04125498 — The S-CARE Trial: Manual Treatment for C-sections Scars, a Pilot Study. · NA · suspended
NCT03440957 — Osteopathy Treatment for Cancer Pain Related to the Confinement to Bed · NA · completed

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05726929 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Toulousain d'Ostéopathie
Last refreshed: 18 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05726929.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing